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ABSTRACT
The BRAF V600E mutation, already a well-established biomarker in the treatment of metastatic melanoma, has 
been extensively studied in patients with metastatic colorectal cancer (CRC) in recent years. It was revealed that 
this mutation occurs in about 10% of CRC patients. It has been proven to be a negative prognostic factor, although 
more recent studies indicate a complex association of this effect with the state of genes responsible for the repair 
of “mismatch” DNA damage. Although the predictive value of the BRAF V600E mutation for chemotherapy and 
targeted treatment remains the subject of controversy, the guidelines of international scientific societies highlight 
the need for a different approach to systemic treatment of patients in this population. Numerous treatment op-
tions are currently evaluated: from the intensification of the classic chemotherapy regimens administered in the 
first-line setting to the innovative combinations of targeted drugs aimed at eliminating the influence of BRAF V600E 
mutation on signal transduction pathways that are crucial for carcinogenesis. The following review is intended 
to bring this complex topic to the attention of oncologists who deal with the treatment of gastrointestinal cancer 
in clinical practice. 
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Introduction
Colorectal cancer (CRC) is diagnosed every year in 
approximately 1.4 million patients worldwide, includ-
ing more than 18,000 patients in Poland [1, 2]. Because 
five-year survival rates are highly unsatisfactory (ap-
proximately 60% in Europe, approximately 50% in 
Poland), there is huge demand for the development of 
new, more effective treatment options. 
Over the last three decades, personalised oncology 
has been introduced and intensively developed. Along 
with a better understanding of the mechanisms behind 
cancer growth, its invasive nature, and complex inter-
actions with the microenvironment, new therapeutic 
options have been increasingly adapted according to 
the unique profile of the patient. Increased knowledge 
about prognostic factors allowed the prediction of the 
dynamics of disease and adjust the intensity of treat-
ment accordingly. The growing number of predictive 
biomarkers potentially reduces the chance of therapy 
failure. 
All these advances have prolonged the median sur-
vival of patients with advanced CRC from the 16 months 
offered by the cytotoxic doublet 10 years ago [3] to over 
30 years with use of modern strategies of combination 
therapy, including drugs targeting epithelial growth fac-
tor receptor (EGFR) and vascular endothelial growth 
factor (VEGF) [4]. Improvement of the results, how-
ever, does not affect all patients equally. Similarly to 
other malignancies, attention of researchers is focused 
on identified groups of patients with particularly poor 
prognosis. 
The importance of the role of proto-oncogenic 
BRAF kinase (type B rapid accelerated fibrosarcoma) 
in carcinogenesis was established in 2002 by the Cancer 
Genome Project group research [5]. BRAF deregula-
tion, common in various cancers, and the most frequent 
in melanoma, colorectal cancer, and gliomas, has been 
the subject of intensive research. BRAF acts mainly as 
a regulatory kinase, one of the transducers of the signals 
from growth factor membrane receptors. Specifically, it 
is one of transmitters in mitogen-activated protein kinase 
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signalling pathway (MAPK, or RAS-RAF-MEK-ERK), 
being a crucial pathway regulating the proliferative 
activity of epithelial cells (Fig. 1). The BRAF gene can 
be the subject of different activating mutations. The 
mutations in codon 600 have been specifically associated 
with strong activation of the MAPK pathway, which is 
known to drive key processes for carcinogenesis: prolif-
eration, invasion, and angiogenesis. The development of 
targeted molecules against mutant BRAF (vemurafenib, 
dabrafenib) as well as against MEK kinase activated 
directly by BRAF (trametinib, cobimetinib) led to a sig-
nificant improvement in the prognosis of patients with 
metastatic melanoma with the BRAF V600 mutation. 
Spectacular effects of BRAF inhibition in melanoma 
drew oncologists’ attention to other cancers, character-
ised by a high frequency of this mutation. In this respect, 
one of the most promising appeared to be metastatic 
CRC (mCRC). 
Some negative effects of the BRAF V600 mutation on 
the prognosis of CRC patients have been demonstrated, 
and its occurrence has been associated with potential 
resistance to some forms of systemic treatment. There 
are also data on possible intensification of therapy, as 
well as attempts of causal interventions being effective 
in this group of patients with poor prognosis. As new 
discoveries are translated into clinical practice, BRAF 
is gaining importance as another factor influencing the 
optimal therapeutic strategy.
This article aims to summarise current knowledge 
and make oncologists treating mCRC patients familiar 
with BRAF clinical potential.
Role in carcinogenesis
The adenoma-adenocarcinoma sequence, now 
considered the classic pathway of colon cancer carcino-
genesis, is initiated by the knock-out of the APC gene 
and the development of chromosomal instability. Other 
changes, such as TP53 knock-out and KRAS or BRAF 
activation, take place in subsequent stages [6]. 
An alternative route of carcinogenesis has been 
proposed based on the genome analysis of serrated 
adenocarcinomas of which serrated adenomas has been 
shown to be precorsor lesions. It has been revealed that 
hyperactivation of BRAF, as well as the acquisition of 
CpG island methylator phenotype (CIMP), are the early 
stages of their pathogenesis [7]. Subsequent deactivat-
ing mutations CDKN2A (p16) and TP53 and activation 
of WNT/b-catenin pathway lead to the formation of 
adenocarcinoma with specific features. 
The importance of the MAPK pathway in the patho-
physiology of colorectal cancer is widely recognised. 
The BRAF gene located on chromosome 7 encodes one 
of the three RAF family serine-threonine kinases (the 
other two are ARAF and CRAF). The best described 
consequence of kinase activation is MAPK-dependent 
stimulation of growth and proliferation. However, the 
activation of parallel regulatory pathways regulated by 
RAF family proteins has also been described, resulting 
in the occurrence of crucial features of tumorigenesis: 
increased mobility and the development of resistance 
to mechanisms inducing cell death [8]. 
Occurrence and predictive value
BRAF mutations occur in about 15% of all human 
tumours [5] and in about 10% of mCRC cases (Table 1) 
[9–13]. The most common mutation is located in exon 
15 of the gene, resulting in the substitution of a small 
hydrophobic valine by the larger, polar glutamic acid in 
codon 600 (V600E). The resultant altered kinase con-
formation is characterised by activity around 10 times 
stronger compared to the wild type [5]. It is worth noting 
that in mCRC this mutation almost never coexists with 
KRAS and NRAS mutations, but it may coexist with 
mutations in the PIK3CA gene (catalytic subunit alpha 
of phosphatidylinositol kinase). 
Characteristic clinical and pathological features of 
colorectal cancer associated with the BRAF V600E mu-
tation include the following: more frequent occurrence 


















Figure 1. Simplified scheme of the most important signalling 
pathways regulating the growth and differentiation of epithelial 
tumours
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Table 1. Incidence of BRAF mutations in large clinical trials
Publication (n)        Study/database BRAF V600E BRAF nonV600E 
Seymour et al. (2013) [9]
(n = 696) 
PICCOLO 9.1% (n = 63) N/A
Venderbosch et al. (2014) [10] 
(n = 3063) 
CAIRO, CAIRO2, COIN, FOCUS 8.2% (n = 250) N/A
Modest et al. (2016) [11] 
(n = 1239) 
FIRE-1, FIRE-3, AIOKRK0207, AIOKRK0604, 
RO91
6.0% (n = 74) N/A
Cremolini et al. (2015) [12] 
(n = 629)
Dedicated database of Italian centres 12.2% (n = 77) 1.6% (n = 10)
Jones et al. (2017) [13]  
(n = 9643) 
Mayo Clinic, MD Anderson, Foundation 
Medicine
7.9% (n = 757) 2.2% (n = 208)
In total (n = 15,270) 8.7% (n = 1221) 2.1% (n = 218)
 
Table 2. Difference in treatment outcomes and survival parameters depending on the status of the BRAF mutation
Study Median PFS (months) Median OS (months)
BRAF WT BRAFmut BRAF WT BRAFmut
Modest et al. (2016) [11] (n=239)
Pooled analysis FIRE-1; FIRE-3; AIO-KRK0604; AIO-KRK 0207; RO91
First line, different cytotoxic regimens ± bevacizumab
10.3 7.4 26,9 11,7
(P < 0.001) (P < 0.001)
Venderbosch et al. (2014) [10] (n = 3063) 
Polled analysis CAIRO; CAIRO2; COIN; FOCUS
First line, different cytotoxic regimens ± bevacizumab
7.7 6.2 17.2 11.4
(P < 0.001) (P < 0.001)
(right-sided) primary tumour location, a higher clinical 
stage, tendency for intraperitoneal metastases (perito-
neal carcinomatosis), more frequently mucous pheno-
type, lower differentiation grade, and often concomitant 
microsatellite instability (MSI) [14]. 
Data from the majority of large clinical trials indicate 
a negative prognostic value of the BRAF V600E muta-
tion at all stages of the disease. 
The results of the PETACC-3 study, as well as cohort 
studies [15–17] involving patients undergoing radical 
resection, indicate that the presence of the BRAF mu-
tation adversely affects overall survival (OS), but not 
relapse-free survival (RFS). 
Similarly, the negative prognostic value of BRAF mutation 
is observed in metastatic disease (Table 2). Polled analysis of 
data from large clinical trials recruiting mCRC patients with 
no prior systemic treatment (CAIRO 1 and 2, COIN, FO-
CUS; n = 3063) showed a significant effect of BRAF mutation 
on median OS: 11.4 vs. 17.2 months; HR 1.91 (1.66–2.19), 
P = 0.001 and median progression-free survival (PFS): 
6.2 vs. 7.7 months; HR 1.34 (1.17–1.54), P < 0.001 [10]. 
A similar analysis of the AIO group data (n = 1239) also 
showed a negative effect of the BRAF mutation on OS: 
11.7 vs. 26.9 months; HR 2.99 (2.1–4.25), P < 0.001 and mPFS: 
7.4 vs. 10.3 months; HR 2.19 (1.59–3.02), P < 0.001 [11]. 
Finally, the pooled analysis of FOCUS, COIN, and 
PICCOLO trials (n = 2071) published in December 
2016 showed a significant negative prognostic value of 
BRAF mutation for median OS 10.8 vs. 16.4 months; 
HR 1.49 (1.23–1.80), P < 0.001, without effect on 
PFS [18]. Disease control rate (DCR) in first-line 
treatment did not differ significantly between cancers 
with or without BRAF mutation: in the FOCUS trial: 
HR 1.01 (0.36–2.84), P = 0.97; in the COIN trial: HR 
0.76 (0.49–1.20), P = 0.24. The rate of survival after 
progression differed significantly in favour of patients 
with normal BRAF gene — in the FOCUS trial: HR 
1.65 (1.03–2.67), P = 0.038; in the COIN trial: HR 
1.72 (1.35–2.19), P < 0.001. Based on these findings it 
was concluded that dynamic, symptomatic progression 
occurring during or after first-line treatment contributes 
to worse prognosis, rather than resistance to cytotoxic 
treatment. 
The negative impact of BRAF mutations on progno-
sis is also observed in patients undergoing surgical treat-
ment for oligometastatic disease. Metastatic resections 
are performed less frequently in this group, and PFS and 
OS after such procedures are significantly worse than in 
the general population [19–21]. However, more recent 
reports show that despite this negative effect, patients 
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RR MSI among  
BRAF V600Emut
Lochhead et al. (2013) [25]; CS I–IV 7.6% (81/1060) 52.3% (101/193) 6.88 55.5% (101/182)
Venderbosch et al. (2014) [10]; CS IV 6.8% (197/2910) 34.6% (53/153) 5.09 21.2% (53/250)
Seppälä et al. (2015) [26]; CS I–IV 5.4% (34/634) 57.7% (60/104) 10.69 63.8% (60/94)
Nakaji et al. (2017) [27]; CS I–III 5.4% (23/428) 40.9% (18/44) 7.57 43.9% (18/41)
Taieb et al. (2017) [28]; CS III 7.1% (279/3934) 42.1% (201/477) 5.93 41.9% (201/480)
In total 6.8% (614/8966) 44.6% (433/971) 6.56 41.4% (433/1047)
MSS — microsatellite stable; MSI — microsatellite instability
with mutation treated by experienced multidisciplinary 
teams have better prognosis if they are subjected to 
metastases resections [22, 23].
BRAF V600E mutation is also included into more 
complex prognostic models. In the latest molecular clas-
sification of CRC, it is one of the determinants of the 
subtype CMS1 — an immunological subtype of CRC, 
associated with the activation of the immune system. As 
compared to other CRC subtypes, CMS1 is associated 
with the worst prognosis in metastatic disease (although 
not with the highest recurrence rate in early disease), 
but it is potentially the most sensitive to immunotherapy 
with immune checkpoints inhibitors [24]. 
In summary, the aggressive dynamics of BRAF 
V600E mutated cancer makes the median survival in this 
subgroup half as long as in the general population, and 
due to aggressive progression, less than half of patients 
undergo systemic treatment ≥ 2 line [18]. 
The relationship between BRAF and MSI
Deficiency of mismatch repair (dMMR) leads to 
microsatellite instability (MSI), e.g. accumulation of 
mutations including inclusions or deletions of short 
nucleotide sequences (microsatellites) characterised 
by reduced strength of DNA polymerase binding. This 
process may be associated with hereditary deficiency in 
activity of one of the genes responsible for this type of 
repair (MLH1, MSH2, MSH6, PMS2), which is the es-
sence of Lynch syndrome pathogenesis (HNPCC — he-
reditary non-polyposis colorectal cancer). However, 
a more frequent cause of MSI is sporadically occurring 
loss of function of one of aforementioned genes (most 
often in the epigenetic mechanism). 
It was noticed that BRAF V600E mutation is several 
times more frequent in MSI cancers caused by sporadically 
occurring dysfunction of MMR (Table 3) than in MSS 
(microsatellite stable) cancers [10, 25–28]; whereas BRAF 
V600E mutation almost never occurs in cancers developed 
in the course of Lynch syndrome [29]. The data shown in 
table 3 demonstrate that up to 42% of all BRAF V600E 
mutations in colon cancer coexist with microsatellite insta-
bility, although when limited only to disseminated cancers 
this rate decreases to around 20% (Table 3). 
The nature of the relationship between BRAF muta-
tion and MSI occurrence is the subject of controversy. 
The genomic instability accompanying MMR deficiency 
seems to be a simple explanation of increased mutations 
frequency in general, including those in BRAF. This hy-
pothesis, however, does not explain lower frequency of 
RAS mutations in this population, as well as the aforemen-
tioned absence of BRAF mutations in HNPCC cancers.
Several authors have noticed that the negative 
prognostic effect of BRAF V600E mutation on overall 
survival is lower or completely absent in the case of 
coexistent microsatellite instability [25, 28, 30, 31]. 
This is consistent with the previously reported, less fre-
quent coexistence of BRAF V600E mutation with MSI 
in disseminated disease, as compared to the general 
population (this would indicate that the negative effect 
of BRAF V600E mutation on survival at disseminated 
stage is mainly caused by cancers without microsatellite 
instability). The reason for this association is still not 
clear, but it is worth noting that in research exploring this 
subject the patients diagnosed in stage IV were under-
represented, and the status of biomarkers (RAS, BRAF, 
MSI) was most commonly assessed in primary tumours, 
thereby not taking into account the heterogeneity of 
tumour phenotype in space (metastasis vs. primary 
tumour) and in time (patients untreated vs. resistant to 
systemic treatment). 
The relationship between BRAF mutation and MSI 
is complex and not fully understood. Studies on multipa-
rameter molecular classification of CRC indicate that 
these disorders seem to have different consequences 
depending on whether they occur together or sepa-
rately, and whether they occur in local or metastatic 
disease [24, 31]. This issue is becoming increasingly 
important, especially in the context of the recently 
described relationship between MSI and sensitivity of 
mCRC to treatment with immune checkpoint inhibitors 
and subsequent registration of pembrolizumab and 
nivolumab in this indication. 
90
OncOlOgy in clinical practice 2018, Vol. 14, No. 2
Predictive value
The predictive value of BRAF V600E mutation 
for cytotoxic chemotherapy remains controversial. 
A retrospective study showed equivalence of oxaliplatin 
and irinotecan administered in a first-line setting [32]. 
Moreover, it seems that the parameters of response to 
first-line systemic treatment (PFS, DCA, or objective 
response rate — ORR) do not differ significantly in 
cancers with this mutation as compared to the general 
population [10, 18].
The impact of BRAF V600E mutation on efficacy 
of anti-EGFR therapy (cetuximab, panitumumab) 
also remains a matter of controversy. Activating mu-
tations in KRAS and NRAS genes are known negative 
predictive factors of response to drugs in this group. It 
was suggested that activating mutation of BRAF gene 
— a protein that is the next signal transducer directly 
downstream of RAS in this pathway — will also be as-
sociated with resistance to anti-EGFR antibodies. In 
previously treated patients, this effect was observed for 
both antibodies retrospectively [33–35], and then for 
panitumumab in a prospective PICCOLO study [9]. 
Interestingly, a statistically significant predictive value 
of BRAF mutation was not observed in studies on the 
role of anti-EGFR antibodies in first-line combined 
chemotherapy regimens: FIRE-3; AGITG CO.17; 
NORDIC-VII, CRYSTAL, OPUS [4, 36–38]. 
In a meta-analysis published in 2015, Pietrantonio 
et al. analysed data from 10 clinical trials evaluating 
the effect of anti-EGFR drugs on prognosis: six studies 
in first line, two in the second line, and two in subse-
quent lines. There was no benefit adding cetuximab or 
panitumumab to standard treatment (chemotherapy 
or supportive care) in patients with BRAF mutation as 
compared to the mutation-negative population in terms 
of PFS (HR 0.88; 95% CI 0.67–1.14, P = 0.33) as well 
as OS (HR 0.91, 95% CI 0.62–1.34, P = 0.63). 
However, in a meta-analysis published in the same 
year by Rowland et al. data from eight clinical trials 
assessing the impact of anti-EGFR drugs on prognosis 
were analysed: four first-line studies, one in the second 
line, and three in subsequent lines — all of them were 
also analysed in the meta-analysis mentioned above. 
The authors of this publication excluded from analysis 
the studies in which the comparator contained bevaci-
zumab and used a different methodology of statistical 
analysis. They concluded that it is impossible to prove 
the lack of benefits from anti-EGFR therapy in patients 
with BRAF mutation compared to mutation-negative 
patients because they found only statistically insignifi-
cant differences between them: for PFS, HR 0.86 (95% 
CI 0.61–1.21) vs. 0.81 (95% CI 0.70–0.95), respectively; 
for OS, HR 0.97 (95% CI 0.67–1.41) vs. 0.62 (95% CI 
0.50–0.77), respectively. 
Ddistinct features of BRAF mutations 
other than V600E 
Until recently, clinical knowledge about the role of 
BRAF activation in mCRC biology was limited to the 
best-known mutation — V600E. The first descriptions 
of less frequent mutations were published in 2015 [12]; 
however, better characteristics were provided in the 
recent the recent publication by Jones et al. of their 
analysis of genome sequences from almost 10,000 can-
cers from American databases [13]. The incidence of 
BRAF non-V600E mutations is shown in Table 1. 
In this study 112 out of 208 cases of this type of mu-
tation were associated with a decrease and 44 with an 
increase in kinase activity. The biological significance of 
the remaining 52 mutations has not been determined. 
Based on analysis of 101 cases with available clinical 
data, it was revealed that the aforementioned clinical 
and pathological features of the BRAF V600E mutations 
were less frequent in the group of patients with muta-
tions other than V600. 
In particular, BRAF non-V600E mutations were as-
sociated with a better prognosis, not only compared to pa-
tients with V600E mutation, but also compared to the gen-
eral population (median OS 60.7 vs. 11.4 vs. 43.0 months, 
respectively, P < 0.001). This fact is easily explained by 
reduced kinase activity; however, the authors’ review of 
preclinical studies shows the greater complexity of the 
biological mechanism and also the potential for new 
therapeutic targets. 
Intensification of first-line 
chemotherapy
It has been shown that the exposure to all drugs 
active in mCRC (5-FU, oxaliplatin, irinotecan) is as-
sociated with a longer survival [39]. Since patients with 
the BRAF mutation have a significantly lower chance 
of receiving the second and subsequent treatment lines 
[18], the intensification of the first-line regimen may be 
the strategy that gives hope for improvement in their 
prognosis. 
The first study by the Greek HORG group evaluat-
ing the low-intensity FOLFOXIRI regimen (irinote-
can 150 mg/m2 d1; oxaliplatin 60 mg/m2 d1; leuco - 
vorin 200 mg/m2 d1, fluorouracil 400 mg/m2 bolus and 
600 mg/m2 in 22 h infusion d1–2; all repeated every two 
weeks) did not show its advantage as compared to the 
FOLFIRI regimen [40]. 
On the contrary, the phase III clinical trial carried 
out almost simultaneously by the Itatilan GONO re-
search group proved the effectiveness of more aggressive 
(classic) version of the FOLFOXIRI scheme (irinote-
can 165 mg/m2 d1; oxaliplatin 85 mg/m2 d1; leucovorin 
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200 mg/m2 d1, fluorouracil 3,200 mg/m2 in 48-h infusion 
from d1; all repeated every two weeks), compared to the 
standard FOLFIRI scheme in patients with unresect-
able CRC, regardless of RAS and BRAF gene status. In 
the experimental group, there were significantly more 
neurotoxicity and neutropaenic episodes of grade 
3–4 according to the CTCAE (Common Toxicity Cri-
teria — Adverse Events) although frequency of febrile 
neutropaenia was < 10% and did not significantly differ 
between the arms. ORR (66% vs. 31%, P = 0.0002); PFS 
(median 9.8 vs. 6.9 months, P = 0.0006) and OS (median 
22.6 vs. 16.7 months, P = 0.032) were significantly better 
[41]. This version of regimen is the best studied so far. 
A single-arm phase II study evaluating the classic 
FOLFOXIRI scheme in combination with bevacizumab 
(BEV) in mCRC patients demonstrated activity of 
this regimen regardless of BRAF gene status [42]. The 
authors conducted thereafter a phase II study evaluat-
ing the response to this chemotherapy regimen only 
in the population of patients with BRAF mutation. 
Polled analysis of both studies showed the following 
effectiveness parameters of FOLFOXIRI regimen in 
patients (n = 25) with BRAF V600E mutation: ORR 
72%; DCR 88%; medians PFS and OS: 11.8 months and 
24.1 months, respectively [43]. Although this comparison 
is associated with obvious limitations, confronting the 
results of this analysis with previously reported survival 
parameters of patients with BRAF V600E mutation 
treated in other studies in a similar period (median 
PFS of seven months and median OS of 12 months) 
indicates clear activity of the FOLFOXIRI scheme in 
this subpopulation. 
The GONO group also conducted a phase III 
study (TRIBE) comparing the effectiveness of FOL-
FOXIRI vs. FOLFIRI, both regimens with addition 
of bevacizumab, in 508 previously untreated mCRC 
patients. Bevacizumab was administered at a dose of 
5 mg/kg bw, using the FOLFOXIRI scheme as in the 
previous studies of this group, while the FOLFIRI 
scheme was used in a more aggressive form (irinote-
can 180 mg/m2 dl; leucovorin 200 mg/m2 d1; fluo-
rouracil 400 mg/m2 — bolus and 2400 mg/m2 — in 
46-h infusion). After 12 cycles all patients received 
maintenance treatment with fluorouracil and bevaci-
zumab. Patients in the active arm significantly more 
frequently experienced neutropaenia, diarrhoea, and 
neurotoxicity. The incidence of febrile neutropaenia 
was below 10% and did not differ significantly between 
the arms. The study showed a significant advantage of 
FOLFOXIRI + BEV as regards to ORR (65% vs. 53%, 
P = 0.013), OS (29.8 vs. 25.8 months, P = 0.03), and 
PFS (12.3 vs. 9.7 months, P = 0.006) in the general 
population. Multivariate subgroup analysis showed no 
significant differences between the studied regimens 
in patients with RAS or BRAF mutation, with a trend 
towards higher activity of four-drug regimen in the 
population with BRAF mutation [44]. 
Unfortunately, no prospective clinical trial compar-
ing FOLFOXIRI with the same regimen in combination 
with bevacizumab has been performed so far. The best 
available study exploring this topic is a pooled analysis 
of the GONO group’s trials, showing the benefit of add-
ing bevacizumab, both in univariate and multivariate 
analysis, with better OS (29.8 vs. 23.6 months, P = 0.014) 
and PFS (12.3 vs. 10.0 months, P = 0.013), but not ORR 
(65.1% vs. 55.7%, P = 0.280) [45]. 
Overall, the combination of FOLFOXIRI + bevaci-
zumab appears to be an active regimen in mCRC patients 
with BRAF mutation (Table 4); however, it should be 
remembered that all studies on this regimen recruited 
only relatively young patients with good performance 
status. Although there is no confirmation of these find-
ings in prospective studies, a combination FOLFOXI-
RI + bevacizumab is mentioned as a therapeutic option 
in mCRC patients with BRAF mutation in international 
guidelines, and many experts consider it as a therapeutic 
standard for mCRC with this molecular profile. 
From a practitioner’s point of view, an important 
issue is selection of second-line treatment after progres-
sion upon a FOLFOXIRI ± BEV scheme. The obvious 
choice may be rechallenge with the first-line regimen; 
however, this strategy, although widely used, seems to 
be justified in patients with a long time to progression, 
which in mCRC harboring BRAF mutation it is an 
exception rather than the rule. For this reason, new 
strategies for combined systemic treatment are being 
developed, based on the use of drugs targeting the key 
molecular mechanism – MAPK pathway activated by 
mutant BRAF kinase. 
Strategies for blocking BRAF in mCRC 
Since the discovery of the role of BRAF as a driver 
of tumour growth, numerous inhibitors of this kinase 
have been studied. Two currently commercialised drugs 
are vemurafenib (Zelboraf™, Roche) and dabrafenib 
(Tafinlar™, Novartis) — both have been approved for 
the treatment of advanced melanoma with the BRAF 
V600 mutation. Further BRAF inhibitors have also 
been developed: LGX818 (encorafenib; Novartis), CEP-
32496 (Ambit Biosciences Corporation), XL281 (Ex-
elixis), HM95573 (Hanmi), ASN003 (BRAF + PI3K, 
Asana Biosciences), LXH254 (pan-RAF, Novartis). Due 
to the very high activity of BRAF inhibitors in mela-
noma therapy, numerous studies have been initiated to 
assess the effectiveness of these drugs in the treatment 
of other cancers with the same molecular alteration. In 
2015, Kopetz et al. presented data from the phase II 
study on anti-BRAF monotherapy in previously treated 
92
OncOlOgy in clinical practice 2018, Vol. 14, No. 2




Response rate Median PFS (months) Median OS (months)
Intervention Comparator Intervention Comparator Intervention Comparator
GONO Falcone et al. [41] 
(n = 244)
FOLFOXIRI vs. FOLFIRI
66% 41% 9.8 6.9 22.6 16.7
(P = 0.0002) (P = 0.0006) (P = 0.032)
TRIBE (n = 508) [44]
FOLFOXIRI + bevacizumab 
vs. FOLFIRI + bevacizumab
65% 53% 12.3 9.7 29.8 25.8
(P = 0.013) (P = 0.006) (P = 0.03)
GONO Loupakis et al. [43] 
BRAFmut (n = 25) 
Pooled analysis of phase II 
studies
FOLFOXIRI + bevacizumab
72% ND 11.8 ND 24.1 ND
ND ND ND
TRIBE BRAFmut (n = 28) [44]
FOLFOXIRI + bevacizumab 
vs. FOLFIRI + bevacizumab
56% 42% 7.5 5.5 19.0 10.7
ND ND ND


































Figure 2. Resistance to BRAF blocking by feedback activation of EGFR signalling
patients with mCRC with the V600E mutation [46]. The 
activity of this strategy was not very encouraging, with 
an ORR of 5% and a median PFS of 2.1 months. As 
the results of similar studies published by other authors 
were comparable [47, 48], further research focused on 
finding resistance mechanisms. 
It has been demonstrated that BRAF blocking results 
in reactivation of MAPK pathway in the EGFR-depen-
dent mechanism (Figure 2) [49, 50] and that the blockage 
of the latter may potentially overcome this resistance. 
Several studies have explored the combination 
of BRAF inhibitor with EGFR blocking, showing 
promising activity [51, 52]. Subsequent studies have 
evaluated the addition of MEK inhibitor, PI3K inhibi-
tor, or a cytotoxic drug to double blockade. In the phase 
II SWOG 1406 trial with previously treated mCRC 
patients with BRAF V600 mutation, the benefit of 
adding BRAF inhibitor to the combination of cetuxi-
mab and irinotecan was evaluated. In a population of 
106 randomised patients a significant reduction in the 
relative risk of progression by 58% (HR 0.42, 95% CI 
0.26–0.66) was shown with median PFS of 4.4 months 
(IRI + CET + WEM) vs. 2.0 months (IRI + CET). 
The ORR in the experimental arm increased from 4% 
to 16% and DCR from 22% to 67%. Adverse reactions 
of grade 3–4 according to the CTCAE scale were more 
frequent in the experimental arm — neutropaenia (28% 
vs. 7%), anaemia (13% vs. 0%), and nausea (15% vs. 0%) 
[53–55]. With the cumulating of data on multi-level 
BRAF interaction with parallel signalling pathways, new 
clinical trials are exploring the combination of BRAF 
inhibition with other drugs (Table 5). 
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Table 5. Ongoing clinical trials in BRAFmut mCRC, with no published results
Evaluated regimens Phase NIH number
encorafenib (BRAF antagonist) + binimetinib (MEK antagonist) I/II NCT01543698
encorafenib + cetuximab ± binimetinib III NCT02928224
vemurafenib + cetuximab + irinotecan I NCT01787500
dabrafenib, trametinib, panitumumab — various combinations II NCT01750918
vemurafenib + cetuximab + 5-fluorouracil II NCT02291289
dactolisib (PI3K antagonist) + binimetinib I NCT01337765
buparlisib (PI3K antagonist) + binimetinib I NCT01363232
LGK974 (beta-catenin antagonist) ± PDR001 (anti-PD-1 antibody) I NCT01351103
irinotecan + AZD1775 (Wee1 antagonist) I NCT02906059
Summary
BRAF V600E mutation is an independent negative 
prognostic factor in colorectal cancer, although the 
presence of other molecular changes, in particular MSI, 
seems to modulate this mechanism. The negative effect 
of this disorder is observed consistently in both locally ad-
vanced and metastatic disease. It seems to result primar-
ily from aggressive dynamics of the disease and rapidly 
progressing recurrences after first-line treatment, rather 
than from resistance to cytotoxic treatment. The recently 
described, less frequent BRAF mutations (outside of 
codon 600) are not associated with worse prognosis. 
The predictive value of BRAF V600E mutation is 
a subject of controversy. Mutation may be associated 
with resistance to treatment with EGFR inhibitors; 
however, data on this subject are not consistent, suggest-
ing potential heterogeneity in this area. Intensification 
of first-line chemotherapy to FOLFOXIRI + BEV 
regimen seems to be an effective therapeutic strategy in 
patients with BRAF V600E mutation, but the evidence 
suporting such strategy does not come from prospective 
studies. Identification of the importance of BRAF mu-
tations in tumour biology, including colorectal cancer, 
have allowed the design of molecular targeted therapies 
of causative nature, suppressing the negative effect of 
excessive BRAF kinase activity and MAPK pathway.
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